scholarly journals Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial

2018 ◽  
Vol Volume 11 ◽  
pp. 8575-8587 ◽  
Author(s):  
Yi-Long Wu ◽  
Chong-Rui Xu ◽  
Cheng-Ping Hu ◽  
Jifeng Feng ◽  
Shun Lu ◽  
...  
Sign in / Sign up

Export Citation Format

Share Document